Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2012-03-13 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 24.9KB
Regulatory Filings
2012-03-13 English
Allied announces successful implant of CardioCel 2 pages 192.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group about the successful implantation of their ADAPT CardioCel patch in a preclinical study. It describes the study details, technology background, and future plans for data release. There are no financial statements, earnings data, regulatory certifications, or management changes. The content is a corporate announcement about a product development milestone and clinical study progress, not a financial report or regulatory filing. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings. It is a general corporate announcement about a technology and study update, which aligns best with the Regulatory Filings (RNS) category as a general announcement that does not fit other specific categories.
2012-03-12 English
Allied announces updated regulatory strategy for CardioCel 3 pages 193.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group providing updates on the global regulatory strategy for the CardioCel cardiovascular patch. It discusses progress with regulatory bodies such as the Australian Therapeutic Goods Administration (TGA), European CE Marking, and the US FDA. The content focuses on regulatory approval submissions and anticipated timelines for market authorization. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about regulatory progress rather than a financial report or detailed investor presentation. It is also longer than 5,000 characters and contains substantive information about regulatory strategy updates. Therefore, the document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit into more specific categories.
2012-03-04 English
Investor Roadshow Presentation 21 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is a presentation dated March 2012 from Allied Healthcare Group (AHG). It contains an overview of the company, its subsidiaries, product pipelines, market potential, management team, and strategic milestones. The content is structured as a detailed investor presentation with forward-looking statements, business strategy, and financial highlights such as revenue and market cap. There are no actual financial statements, audit opinions, or regulatory certifications included. The document is not a formal report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief earnings release or a regulatory filing. It is clearly a detailed presentation aimed at investors, describing the company's business, strategy, and growth prospects. Therefore, the appropriate classification is Investor Presentation (IP).
2012-03-01 English
Half Yearly Report and Accounts 22 pages 136.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled as a 'Half Yearly Report (Appendix 4D) for the 6 months ended 31 Dec 2011' and includes detailed financial results, directors' report, financial report, directors' declaration, and audit report. It contains comprehensive financial data and analysis for the half-year period, including revenues, losses, dividends, net tangible assets, and operational highlights. The presence of an audit report and independence declaration further supports this classification. The document is not merely an announcement or a brief summary but a full interim financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2012
2012-02-29 English
Allied`s Coridon to develop HPV Vaccine 3 pages 163.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Allied Healthcare Group about Coridon developing a therapeutic HPV vaccine. It contains no financial statements, no regulatory form references, no voting results, no management changes, no earnings data, and no detailed financial or governance information. The content is primarily a corporate announcement about a new development project and collaboration, typical of a general regulatory announcement. The document length is 6811 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a certification. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2012-02-27 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.